1. Articles in category: Review

    1-24 of 136 1 2 3 4 5 6 »
    1. Comparison of diagnosing and staging accuracy of Pet (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

      Comparison of diagnosing and staging accuracy of PET (CT) and MIBG on patients with neuroblastoma: Systemic review and meta-analysis.

      J Huazhong Univ Sci Technolog Med Sci. 2017 Oct;37(5):649-660

      Authors: Xia J, Zhang H, Hu Q, Liu SY, Zhang LQ, Zhang A, Zhang XL, Wang YQ, Liu AG

      Read Full Article
      Mentions: Staging MIBG
    2. Diet, exercise modifications can have ‘tremendous impact’ on pediatric cancer outcomes

      Joya Chandra Keri Schadler Diet and exercise may improve treatment outcomes among pediatric patients with cancer, according to a study conducted at The University of Texas MD Anderson Children’s Cancer Hospital. In addition, introducing energy balance interventions may reduce the risk for late effects during survivorship. Researchers at MD Anderson reviewed 67 pediatric oncology studies to evaluate the relationship between diet and exercise.

      Read Full Article
      Mentions: Treatment
    3. 11q deletion in neuroblastoma: a review of biological and clinical implications.

      11q deletion in neuroblastoma: a review of biological and clinical implications.

      Mol Cancer. 2017 Jun 29;16(1):114

      Authors: Mlakar V, Jurkovic Mlakar S, Lopez G, Maris JM, Ansari M, Gumy-Pause F

      Abstract Deletion of the long arm of chromosome 11 (11q deletion) is one of the most frequent events that occur during the development of aggressive neuroblastoma. Clinically, 11q deletion is associated with higher disease stage and decreased survival probability.

      Read Full Article
    4. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.

      Pediatr Blood Cancer. 2017 May;64(5):

      Authors: Jiménez I, Baruchel A, Doz F, Schulte J

      Abstract The last few years have seen the identification of pharmacologic approaches to target bromodomain and extraterminal (BET) proteins for cancer treatment.

      Read Full Article
      Mentions: Treatment
    5. Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Clinical manifestations of neuroblastoma with head and neck involvement in children.

      Int J Pediatr Otorhinolaryngol. 2017 Jun;97:157-162

      Authors: Alvi S, Karadaghy O, Manalang M, Weatherly R

      Abstract OBJECTIVE: The purpose of our study is to review our 15-year experience with pediatric patients who have been diagnosed with neuroblastoma, and to determine their most frequent head and neck manifestations and symptoms. STUDY DESIGN: Retrospective chart review of electronic medical record.

      Read Full Article
    6. Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review.

      Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review.

      Pediatr Blood Cancer. 2017 Feb 28;:

      Authors: Diorio C, Salena K, Ladas EJ, Lam CG, Afungcwhi GM, Njuguna F, Marjerrison S

      Abstract Traditional and complementary medicine (T&CM) strategies are widely utilized in pediatric oncology, with many families reporting T&CM use with the intention to cure cancer.

      Read Full Article
    7. Traditional and complementary medicine used with curative intent in childhood cancer: A systematic review

      Traditional and complementary medicine (T&CM) strategies are widely utilized in pediatric oncology, with many families reporting T&CM use with the intention to cure cancer. Study of T&CM agents presents many challenges, as a heterogeneous group of agents and techniques are used for a variety of different purpose in many different oncologic conditions. We present a systematic review of the literature examining published reports in which T&CM agents are used with an intention of cure.

      Read Full Article
    8. Prevalence of cardiovascular late sequelae in long-term survivors of childhood cancer: A systematic review and meta-analysis

      Cardiovascular diseases are well-known late effects of childhood cancer and research on these late effects is a highly important emerging field. We conducted a systematic review with a meta-analysis to give an overview of the current evidence and the prevalence of late cardiovascular events.

      Read Full Article
    9. Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review.

      Treatment and outcome of neuroblastoma with intraspinal extension: A systematic review.

      Pediatr Blood Cancer. 2017 Feb 02;:

      Authors: Kraal K, Blom T, van Noesel M, Kremer L, Caron H, Tytgat G, van der Pal H

      Abstract We performed a systematic review to define the long-term health problems and optimal treatment strategy for patients with neuroblastoma with intraspinal extension. Of 685 identified studies, 28 were included in this review.

      Read Full Article
      Mentions: Treatment
    10. Evaluation and Management of Hearing Loss in Survivors of Childhood and Adolescent Cancers: A Report From the Children's Oncology Group

      Hearing loss (HL) is common in childhood cancer survivors exposed to platinum chemotherapy and/or cranial radiation and can severely impact quality of life. Early detection and appropriate management can mitigate academic, speech, language, social, and psychological morbidity resulting from hearing deficits. This review is targeted as a resource for providers involved in aftercare of childhood cancers.

      Read Full Article
    11. Energy metabolism in neuroblastoma and Wilms tumor.

      "In this review we focus on metabolic pathways in neuroblastoma (NB) and Wilms tumor (WT), the two most frequent solid tumors in children. Both tumor types show alterations of the OXPHOS system and glycolytic features. Chromosomal alterations and activation of oncogenes like MYC or inactivation of tumor suppressor genes like TP53 can in part explain the changes of energy metabolism in these cancers. The strict dependence of cancer cells on glucose metabolism is a fairly common feature among otherwise biologically diverse types of cancer. Therefore, inhibition of glycolysis or starvation of cancer cells through glucose deprivation via a high-fat low-carbohydrate ...

      Read Full Article
    12. Innovations for phase I dose-finding designs in pediatric oncology clinical trials.

      Innovations for phase I dose-finding designs in pediatric oncology clinical trials.

      Contemp Clin Trials. 2016 Jan 26;

      Authors: Doussau A, Geoerger B, Jiménez I, Paoletti X

      Abstract Phase I oncology clinical trials are designed to identify the optimal dose that will be recommended for phase II trials. In pediatric oncology, the conduct of those trials raise specific challenges, as the disease is rare with limited therapeutic options.

      Read Full Article
    13. Late Effects Surveillance Recommendations among Survivors of Childhood Hematopoietic Cell Transplantation: A Children's Oncology Group Report.

      "For the most recent review cycle, over 800 articles from the medical literature relevant to childhood cancer and HCT survivorship were reviewed, including 586 original research articles. Provided here-in is an organ system-based overview that emphasizes the most relevant COG recommendations (with accompanying evidence grade) for the long-term follow-up care of childhood HCT survivors (regardless of current age) based on a rigorous review of the available evidence. These recommendations cover both autologous and allogeneic HCT survivors, those transplanted for non-malignant diseases, and those with a history of chronic GVHD."

      Read Full Article
      Mentions: COG GvHD
    14. Cell Proliferation in Neuroblastoma.

      Cell Proliferation in Neuroblastoma.

      Cancers (Basel). 2016;8(1)

      Authors: Stafman LL, Beierle EA

      Abstract Neuroblastoma, the most common extracranial solid tumor of childhood, continues to carry a dismal prognosis for children diagnosed with advanced stage or relapsed disease. This review focuses upon factors responsible for cell proliferation in neuroblastoma including transcription factors, kinases, and regulators of the cell cycle.

      Read Full Article
    15. Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

      Assessment of Primary Site Response in Children With High-Risk Neuroblastoma: An International Multicenter Study.

      J Clin Oncol. 2016 Jan 11;

      Authors: Bagatell R, McHugh K, Naranjo A, Van Ryn C, Kirby C, Brock P, Lyons KA, States LJ, Rojas Y, Miller A, Volchenboum SL, Simon T, Krug B, Sarnacki S, Valteau-Couanet D, von Schweinitz D, Kammer B, Granata C, Pio L, Park JR, Nuchtern J

      Read Full Article
    16. Aurora Kinase Inhibitors: Current Status and Outlook.

      Aurora Kinase Inhibitors: Current Status and Outlook.

      Front Oncol. 2015;5:278

      Authors: Bavetsias V, Linardopoulos S

      Abstract The Aurora kinase family comprises of cell cycle-regulated serine/threonine kinases important for mitosis. Their activity and protein expression are cell cycle regulated, peaking during mitosis to orchestrate important mitotic processes including centrosome maturation, chromosome alignment, chromosome segregation, and cytokinesis.

      Read Full Article
    17. Palliative Care as a Standard of Care in Pediatric Oncology.

      Palliative Care as a Standard of Care in Pediatric Oncology.

      Pediatr Blood Cancer. 2015 Dec;62(S5):S829-S833

      Authors: Weaver MS, Heinze KE, Kelly KP, Wiener L, Casey RL, Bell CJ, Wolfe J, Garee AM, Watson A, Hinds PS

      Abstract The study team conducted a systematic review of pediatric and adolescent palliative cancer care literature from 1995 to 2015 using four databases to inform development of a palliative care psychosocial standard.

      Read Full Article
    18. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.

      Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.

      J Pediatr Surg. 2015 Nov 5;

      Authors: Murphy JM, Lim IP, Farber BA, Heaton TE, Basu EM, Roberts SS, Modak S, Kushner BH, LaQuaglia MP

      Abstract PURPOSE: Treatment of progression in high-risk neuroblastoma remains challenging despite improved survival. We retrospectively evaluated outcomes in children with a first progression that included soft-tissue masses.

      Read Full Article
      Mentions: Relapse MYCN
    19. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.

      "Since 2003, high-risk neuroblastoma (HR-NB) patients at our center received anti-GD2 antibody 3F8/GM-CSF + isotretinoin - but not myeloablative therapy with autologous stem-cell transplantation (ASCT). Post-ASCT patients referred from elsewhere also received 3F8/GM-CSF + isotretinoin. We therefore accrued a study population of two groups treated during the same period and whose consolidative therapy, aside from ASCT, was identical. We analyzed patients enrolled in 1st complete/very good partial remission (CR/VGPR). Their event-free survival (EFS) and overall survival (OS) were calculated from study entry. Large study size allowed robust statistical analyses of key prognosticators including MYCN amplification, minimal residual disease (MRD ...

      Read Full Article
      Mentions: Immunotherapy MYCN
    20. More than the genes, the tumor microenvironment in neuroblastoma.

      "However it is now clear that not only genetic events play a role but that the tumor microenvironment (TME) substantially contributes to the biology of neuroblastoma. In this article, we present a comprehensive review of the literature on the contribution of the TME to the ten hallmarks of cancer in neuroblastoma and discuss the mechanisms of communication between neuroblastoma cells and the TME that underlie the influence of the TME on neuroblastoma progression. We end our review by discussing how the knowledge acquired over the last two decades in this field is now leading to new clinical trials targeting the ...

      Read Full Article
      Mentions: MYCN
    1-24 of 136 1 2 3 4 5 6 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles